# ARK Invest

Type: Company

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/ark-invest
Canonical HTML page: https://getbiobrief.com/entity/ark-invest

## Recent coverage (1 stories)

### Cathie Wood’s ARK Invest Doubles Down on CRISPR Therapeutics Amid Market Dip
2026-03-11 11:48:57 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

ARK Invest, led by Cathie Wood, has significantly increased its position in CRISPR Therapeutics (CRSP), signaling continued high conviction in the gene-editing pioneer despite recent market fluctuations. This move highlights Wood's strategy of doubling down on disruptive genomic technologies during periods of valuation compression.
Full story: https://getbiobrief.com/story/cathie-wood-ark-invest-crispr-therapeutics-buy-dip

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.